Fact-Checkers Find Few Flaws in Clinton's Healthcare Claims

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: The Hill, Sam Baker (9/6/12)

"Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of 'fact' are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments."

The Hill, Sam Baker

Bill Clinton's long, detailed arguments on healthcare are mostly holding up under scrutiny from the cottage industry of political fact-checkers.

Healthcare was a big part of Clinton's policy-laden speech Wednesday night at the Democratic convention in Charlotte, N.C. He defended President Obama's healthcare law, including its controversial Medicare savings, and took a hard swipe at Republicans' proposals for Medicaid.

Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of "fact" are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments.

The biggest criticism centers around Clinton's claim that healthcare costs aren't rising as quickly as they did in the past. . .View Full Article

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports (02/10/2026)

Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.

Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent.

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Source: Streetwise Reports (02/09/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.

FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
Source: Streetwise Reports (02/06/2026)

TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study.

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert (02/02/2026)

MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.